ABCL Stock — AbCellera Biologics Inc.

AbCellera Biologics Inc. (ABCL)

Updated October 2, 2026.

ABCL is a Stock. Total return is -76.7% over the past 5.8 years, 204.5 points behind SPY at 127.8%.

AbCellera Biologics is a biopharmaceutical company developing antibody-based medicines for unmet medical needs, with lead programs in Phase 1 and Phase 2clinical trials targeting conditions including vasomotor symptoms and autoimmune diseases. The company operates through research collaborations and partnerships with major pharmaceutical firms including Eli Lilly, AbbVie, Biogen, and Vertex Pharmaceuticals. AbCellera does not currently distribute to shareholders, making it oriented toward investors seeking long-term capital appreciation rather than income.

ABCL performance versus SPY

Price and return data through 2026-10-02.

Total return is -76.7% over the past 5.8 years, 204.5 points behind SPY at 127.8%. Over the past year its total return — price change plus distributions reinvested — is 129.8%. Its deepest 1-year drawdown was 54.9%.

ABCL key facts

Asset type

Stock

Asset class

Equity

Inception date

12/11/2020

Distribution frequency

None

Last close

$13.74 (as of 2026-10-02)

Market cap

$4,452,410,768

Average volume

3700500.0

Beta

1.322

Payout ratio

0.0%

Forward P/E

27.5482

EPS

$-0.53

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ABCL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 54.9%.

Who may consider ABCL — and who may not

It is a weaker fit for investors who need monthly cash flow (ABCL does not currently distribute); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

Frequently asked questions